CCL23 is a chemokine implicated in inflammation and host defense responses. It has been recently associated with acquired brain damage and stroke outcomes. In this study, we reported the role of CCL23 in Alzheimer’s disease (AD). We evaluated the levels of CCL23 in 659 individuals: cognitively normal, mild cognitive impaired (MCI), and AD patients. Two cross-sectional (study 1, n = 53; study 2, n = 200) and two longitudinal (study 3, n = 74; study 4, n = 332) studies were analyzed separately. CCL23 levels in the blood and/or cerebrospinal fluid (CSF) of each study were measured by immunoassays. Globally, our results suggest a predictive role of CCL23 protein levels both in the plasma in study 3 (hazard ratio (HR) = 2.5 (confidence interval (CI) 95% : 1.2–5.3), p = 0.02) and in the CSF in study 4 (HR = 3.05 (CI 95% : 1.02–5), p = 0.04) in cases of MCI that progress to AD. Moreover, we observed that the APOEɛ4 allele was associated with higher levels of CCL23 in study 2 (470.33 pg/mL (interquartile range (IQR): 303.33–597.76) versus 377.94 pg/mL (IQR: 267.16–529.19), p = 0.01) (APOE genotypes were available in studies 2 and 4). Together, these findings support the role of CCL23 in neuroinflammation in the early stages of AD, suggesting that CCL23 might be a candidate blood biomarker for MCI to AD progression.
Savarin-VuaillatC, RansohoffRM (2007) Chemokines and chemokine receptors in neurological disease: Raise, retain, or reduce?Neurotherapeutics4, 590–601.
2.
PatelVP, KreiderBL, LiY, LiH, LeungK, SalcedoT, NardelliB, PippallaV, GentzS, ThotakuraR, ParmeleeD, GentzR, GarottaG (1997) Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med185, 1163–1172.
3.
YounBS, ZhangSM, BroxmeyerHE, CooperS, AntolK, FraserM, KwonBS (1998) Characterization of CKbeta8 and CKbeta8-1: Two alternatively spliced forms of human beta-chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1. Blood91, 3118–26.
4.
ShihCH, Van EedenSF, GotoY, HoggJC (2005) CCL23/myeloid progenitor inhibitory factor-1 inhibits production and release of polymorphonuclear leukocytes and monocytes from the bone marrow. Exp Hematol33, 1101–1108.
5.
KimJ, KimYS, KoJ (2010) CKB8/CCL23 induces cell migration via the Gi/Goprotein/PLC/PKCδ/NF-κB and is involved in inflammatory responses. Life Sci86, 300–308.
6.
KimSM, SongJ, KimS, HanC, ParkMH, KohY, JoSA, KimYY (2011) Identification of peripheral inflammatory markers between normal control and Alzheimer’s disease. BMC Neurol11, 51.
7.
RiojaI, HughesFJ, SharpCH, WarnockLC, MontgomeryDS, AkilM, WilsonAG, BinksMH, DicksonMC (2008) Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum58, 2257–2267.
8.
YanabaK, YoshizakiA, MuroiE, OgawaF, AsanoY, KadonoT, SatoS (2011) Serum CCL23 levels are increased in patients with systemic sclerosis. Arch Dermatol Res303, 29–34.
9.
SimatsA, García-BerrocosoT, PenalbaA, GiraltD, LloveraG, JiangY, RamiroL, BustamanteA, Martinez-SaezE, CanalsF, WangX, LieszA, RosellA, MontanerJ (2018) CCL23: A new CC chemokine involved in human brain damage. J Intern Med283, 461–475.
10.
ScheltensP, BlennowK, BretelerMMB, de StrooperB, FrisoniGB, SallowayS, Van der FlierWM (2016) Alzheimer’s disease. Lancet388, 505–517.
11.
BazenetC, LovestoneS (2012) Plasma biomarkers for Alzheimers disease: Much needed but tough to find. Biomark Med6, 441–454.
KeshavanA, HeslegraveA, ZetterbergH, SchottJM (2017) Blood biomarkers for Alzheimer’s disease: Much promise, cautious progress. Mol Diagnosis Ther21, 13–22.
16.
HenriksenK, O’BryantSE, HampelH, TrojanowskiJQ, MontineTJ, JerominA, BlennowK, LönneborgA, Wyss-CorayT, SoaresH, BazenetC, SjögrenM, HuWT, LovestoneS, KarsdalMA, WeinerMW (2013) The future of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement6, 115–131.
17.
MattssonN, CullenNC, AndreassonU, ZetterbergH, BlennowK (2019) Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol74, 557.
18.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
19.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
20.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
21.
MontañolaA, de RetanaSF, López-RuedaA, Merino-ZamoranoC, PenalbaA, Fernández-ÁlvarezP, Rodríguez-LunaD, MalageladaA, PujadasF, MontanerJ, Hernández-GuillamonM (2016) ApoA1, ApoJ and ApoE plasma levels and genotype frequencies in cerebral amyloid angiopathy. Neuromolecular Med18, 99–108.
22.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
DuitsFH, PrinsND, LemstraAW, PijnenburgYAL, BouwmanFH, TeunissenCE, ScheltensP, Van Der FlierWM (2015) Diagnostic impact of CSF biomarkers for Alzheimer’s disease in a tertiary memory clinic. Alzheimers Dement11, 523–532.
HarariO, CruchagaC, KauweJSK, AinscoughBJ, BalesK, PickeringEH, BertelsenS, FaganAM, HoltzmanDM, MorrisJC, GoateAM (2014) Ptau-Aβ42 ratio as a continuous trait for biomarker discovery for early stage Alzheimer’s disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry75, 723–731.
29.
KauweJSK, BaileyMH, RidgePG, PerryR, WadsworthME, HoytKL, StaleyLA, KarchCM, HarariO, CruchagaC, AinscoughBJ, BalesK, PickeringEH, BertelsenS, Alzheimer’s Disease Neuroimaging Initiative, FaganAM, HoltzmanDM, MorrisJC, GoateAM (2014) Genome-wide association study of CSF levels of 59 Alzheimer’s disease candidate proteins: Significant associations with proteins involved in amyloid processing and inflammation. PLoS Genet10, e1004758.
30.
HeppnerFL, RansohoffRM, BecherB (2015) Immune attack: The role of inflammation in Alzheimer disease. Nat Rev Neurosci16, 358–372.
31.
LeungR, ProitsiP, SimmonsA, LunnonK, GüntertA, KronenbergD, PritchardM, TsolakiM, MecocciP, KloszewskaI, VellasB, SoininenH, WahlundLO, LovestoneS (2013) Inflammatory proteins in plasma are associated with severity of Alzheimer’s disease. PLoS One8, e64971.
32.
FariaMC, GonçalvesGS, RochaNP, MoraesEN, BicalhoMA, Gualberto CintraMT, Jardim de PaulaJ, José Ravic de MirandaLF, Clayton de Souza FerreiraA, TeixeiraAÔL, GomesKB, Carvalho M dasG, SousaLP (2014) Increased plasma levels of BDNF and inflammatory markers in Alzheimer’s disease. J Psychiatr Res53, 166–172.
33.
GongC, WeiD, WangY, MaJ, YuanC, ZhangW, YuG, ZhaoY (2015) A meta-analysis of C-reactive protein in patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen31, 194–200.
34.
LaiKSP, LiuCS, RauA, LanctôtKL, KöhlerCA, PakoshM, CarvalhoAF, HerrmannN (2017) Peripheral inflammatory markers in Alzheimer’s disease: A systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry88, 876–882.
35.
AziziG, KhannazerN, MirshafieyA (2014) The potential role of chemokines in alzheimer’s disease pathogenesis. Am J Alzheimers Dis Other Demen29, 415–425.
36.
Halks-millerM, SchroederML, HaroutunianV, MoenningU, RossiM, AchimC, PurohitD, MahmoudiM, HorukR (2003) CCR1 is an early and specific marker of Alzheimer’s disease. Ann Neurol54, 638–646.
37.
MagakiS, MuellerC, DicksonC, KirschW (2007) Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol42, 233–240.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
40.
KeeneCD, CudabackE, LiX, MontineKS, MontineTJ (2012) Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer’s disease. Curr Opin Neurobiol21, 920–928.
41.
YuJ-T, TanL, HardyJ (2014) Apolipoprotein E in Alzheimer’s disease: An update. Annu Rev Neurosci37, 79–100.
42.
RingmanJ, ElashoffD (2012) Plasma signaling proteins in persons at genetic risk for Alzheimer disease: Influence of APOE genotype. Arch Neurol69, 757–764.
